Cytokine Release Assay Service

Multiple sclerosis (MS) is characterized by chronic inflammation and demyelination within the central nervous system, stemming from dysregulated immune activation. Cytokines acting as signaling molecules orchestrate this inflammatory cascade. Cytokine release assays (CRAs) enable the precise measurement of cytokine secretion, providing crucial insights into the immunopathogenesis of MS. For further information regarding the products and services provided, project-specific consultation, and pricing, please submit an inquiry here.

CRA in Drug Development

• The Close Association Between MS and Cytokines

The pathological cascade of MS, involving blood-brain barrier (BBB) disruption, inflammatory cell infiltration, and demyelination, is centrally mediated by cytokines such as IL-6 and TNF-α. CRAs allow for the simulation of MS-relevant microenvironments, enabling the evaluation of drug modulation on cytokine networks and preventing excessive immune system activation.

• Key Aspects of CRS Prevention

Immunomodulatory drugs, including monoclonal antibodies, can trigger cytokine release syndrome (CRS) through Fab- or Fc-mediated mechanisms. Our CRA services provide systematic detection of drug-induced cytokine release profiles, identifying potential risk molecules, and delivering crucial data for candidate drug screening.

Multiplex Cytokine Assay Platform

Creative Biolabs offers a cytokine detection platform and expert cytokine detection technology services to support your scientific research needs. Our cytokine detection platform uses fluorescent microspheres coupled with highly specific capture monoclonal antibodies and then adds secondary antibodies to measure the fluorescence intensity of a single microsphere, which can effectively detect multiple cytokines at the same time. The cytokine detection platform has the following features:

• High throughput: Detect multiple indicators simultaneously.
• High efficiency: Short experimental time.
• High sensitivity: ≥0.1 pg/mL.

Fig.1 Production of cytokines and granzyme B after stimulation of peripheral blood mononuclear cells (PBMCs) with SLA for a period of 5 days.¹

Creative Biolabs also offers other detection methods for the CRA assay, including but not limited to Real-time quantitative polymerase chain reaction assay, enzyme-linked immunosorbent assay (ELISA), flow cytometry, intracellular cytokine staining (ICS) analysis.

Personalized Solutions for MS Research

Our CRA services offer tailored experimental designs to address your specific MS research needs, including:

• Targeted analysis using patient-derived cells or serum: We can conduct targeted cytokine analysis using cells or serum obtained directly from MS patients.
• Integration with demyelination animal models: Combine in vitro CRA results with in vivo data from demyelination animal models to gain a comprehensive understanding of disease mechanisms.
• Cell-specific cytokine profiling: Analyze cytokine secretion profiles of specific cell subsets, such as Th17 cells and microglia, to dissect the complex immune microenvironment in MS.

Please connect with us today for a customized CRA solution and fortify your drug development pipeline!

Reference

1. Carrillo, Eugenia, et al. "Cytokine release assays as tests for exposure to Leishmania, and for confirming cure from leishmaniasis, in solid organ transplant recipients." PLoS neglected tropical diseases 9.10 (2015): e0004179. Distributed under Open Access license CC BY 4.0, without modification.